{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-037603","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.143359+00:00","generated_at":"2026-05-17T20:56:50.062623+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Foghorn Therapeutics Q2 2025 net loss narrows to $17.9M; cash runway into 2028; pipeline on track","bullets":["Net loss of $17.9M in Q2 2025, improved from $23.0M in Q2 2024; collaboration revenue $7.6M.","Cash, equivalents and marketable securities $198.7M as of June 30, 2025; cash runway into 2028.","FHD-909 Phase 1 trial in SMARCA4-mutated NSCLC enrolling well; preclinical combo data with pembrolizumab and KRAS inhibitors.","Selective CBP degrader targeting IND in 2026; selective EP300 and ARID1B degrader updates expected Q4 2025.","R&D expenses decreased to $21.8M from $23.8M; G&A expenses decreased to $6.9M from $7.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-037603","json":"https://secwatch.observer/filing/0001628280-25-037603.json","markdown":"https://secwatch.observer/filing/0001628280-25-037603.md","text":"https://secwatch.observer/filing/0001628280-25-037603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025037603/0001628280-25-037603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025037603/fhtx-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:56:50.062623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}